DiaMedica Therapeutics, a biotechnology company, is expanding its clinical development program for DM199 into preeclampsia. Preeclampsia is a severe pregnancy-related condition characterized by high blood pressure and protein in the urine, posing risks to both the mother and the baby.
DM199 is a protein therapeutic that improves blood vessel function. It is believed to lower blood pressure and enhance blood flow to vital organs and the placenta. This mechanism of action is essential in preeclampsia, where reduced blood flow to the placenta contributes to the condition’s severity.
Phase 2 clinical trial results in chronic kidney disease patients with elevated blood pressure showed significant reductions in systolic blood pressure with DM199 treatment. Animal studies have also demonstrated the drug’s safety in pregnant individuals, with no evidence of placental transfer.
The planned preeclampsia trial is designed to be cost-effective, with an estimated enrollment of 120 participants and a budget of approximately $1.5 million. The trial aims to provide proof of concept for DM199’s potential to address preeclampsia.
If successful, DM199 could fill a significant unmet medical need in preeclampsia, where there are currently no approved therapies in the U.S. or Europe. By improving blood pressure control and enhancing placental perfusion, DM199 has the potential to improve outcomes for both mothers and babies affected by this life-threatening condition.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
